• Congenital adrenal hyperplasia may show genotype-phenotype discordance; nevertheless, intrafamilial phenotypic variability is unusual.
Background
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is caused by autosomal recessive mutations in the CYP21A2 gene. Although this disorder can be viewed as a continuum of disorders, phenotypically, it can be divided into classical and non-classical (NC) forms, with the former presenting as salt-wasting (SW) or simple virilizing (SV) CAH. More than 100 CYP21A2 mutations have been reported. However, molecular genetic testing for 9 common mutations and deletions detects approximately 80-98% of disease-causing alleles [1] .
Thyroglobulin (TG) is exclusively synthesized in the thyroid gland. Autosomal recessive mutations in TG lead to permanent congenital hypothyroidism (CH). The combination of CAH and CH occurring in the same individual has not, to our knowledge, been reported in the literature.
Methods

Hormone Assays
Serum cortisol, testosterone, ACTH, DHEA, DHEA-S, androstenedione, FT4, and TSH were measured using competitive chemiluminescent immunoassay (Immulite 2000 Siemens Diagnostics). During follow-up, the median time from the intake of the last hydrocortisone dose until blood sampling was 4.75 h. Plasma renin activity (PRA) was measured using RIA.
Gonadotropin-releasing hormone (GnRH) stimulation test has been performed by measuring plasma LH and FSH concentrations at baseline and 20 and 60 min after intravenous injection of GnRH 2.5 μg/kg (maximum 100 μg).
Reference ranges for TSH and FT4 were 0.55-6 mU/L and 10.2-20.6 pmol/L, respectively.
Genetic Testing CYP21A2 gene deletion and chimeric genes were detected using a commercially available multiplex ligation-dependent probe amplification strategy following the manufacturer's protocol (MRC-Holland, Amsterdam, The Netherlands). CYP21A2 point mutations were detected by targeted multiplex minisequencing after allele-specific PCR amplification of the CYP21A2 gene.
Genetic investigation of CH was performed through a customized targeted Agilent SureSelect pull-down array, designed to screen 1,188 genes, including TG, TPO, TSHR, DUOX2, DUOXA2, IYD, SLC5A5 and SLC26A4. Dataset calls were annotated with dbSNP v137 rsIDs and allele frequencies were computed from several datasets including 1,000 Genomes Phase I (n = 2,818), UK10K whole-exome sequencing studies (n = 4,975) and Exome Aggregation Consortium r0.3 (ExAC) (n = 60,706). Rare variants were selected that affected the protein-coding sequence with the SIFT or Polyphen pathogenicity prediction "possibly damaging" or above for missense variants. All likely pathogenic variants were confirmed by Sanger sequencing.
Subjects Parents (Fig. 1 , I:1 and I:2) The parental medical history is unremarkable. They are unrelated, and the father is Palestinian, while the mother is white British. The father reached a final height of -1.43 SDS, while the mother's height is -0.84 SDS, with a mid-parental height of -1.25 SDS. Molecular analysis of CYP21A2 showed that the mother was heterozygous for the I2 splice mutation, while the father had an apparent normal CYP21A2 copy number and carried the mutations p.V281L and p.I172N on one allele, and a second p.V281L mutation on the other. Sequencing of TG showed a p.R296* mutation in the father and a novel p.T1416Rfs*30 mutation in the mother.
Sibling 1 (Fig. 1, II: 3) This female child was born at term by vaginal delivery with a weight of 3.1 kg and presented at birth with virilized genitalia (Prader 3). The androgen profile performed on day 3 showed markedly increased concentrations of 17-hydroxyprogesterone (17-OHP; 276 nmol/L; normal range 0-5) ( (Fig. 2) , with mild diffusion restriction and avid enhancement after gadolinium administration. Her blood pressure is highnormal (130/90 mm Hg) and her plasma catecholamines and urinary metanephrines are normal; therefore, in the light of the imaging findings, the right adrenal mass is most likely an adrenal adenoma. Adrenal mass appearances have been stable over the last 5 years and the patient has been changed to twice daily dexamethasone treatment, in order to improve compliance and optimize control of the CAH. In addition, she is taking flutamide and metformin in order to mitigate the signs of severe hyperandrogenism and insulin insensitivity.
Sibling 2 ( (Table 1) , but the cortisol response was adequate (peak 722 nmol/L). She is currently asymptomatic at the age of 17.8 years and has regular menstrual cycles. Her final adult height is 154 cm (SDS -1.35), which is well within the target height range, with a weight of 55 kg (SDS +1). She was compound heterozygous for the maternal I2 splice and the paternal p.V281L mutations.
Sibling 3 (Fig. 1, II: 5) This male patient was born at term by caesarean section with a weight of 3.3 kg. The child was diagnosed with CAH on neonatal screening because of the positive family history of CAH (capillary 17-OHP >60 nmol/L). Confirmatory blood tests performed on day 3 of life at a presymptomatic stage revealed serum 17-OHP 276 nmol/L (Table 1) , Na 142 mmol/L, and K 6.2 mmol/L and the child was commenced on hydrocortisone, fludrocortisone, and sodium supplements.
Diagnosis of CH was suspected upon neonatal screening (Guthrie TSH 213 mU/L) and confirmed on day 7 of life with a venous TSH of 248.3 mU/L and FT4 of 17.6 pmol/L on recall (Table 1). Therefore, thyroxine replacement therapy was commenced on the same day at a starting dose of 12.5 μg/kg/day.
He had had poor compliance with medications since the first year of life, with chronically raised 17-OHP (mean value of periodic measurements since diagnosis 53.9 nmol/L), PRA (mean value of periodic measurements since diagnosis 7.87 pmol/mL/h), and TSH (mean value of periodic measurements since diagnosis 28.8 mUI/L) and low FT4 concentrations (below 10 pmol/L, minimum 7.8 pmol/L) detected on several occasions. He is also developmentally delayed. He is a compound heterozygote for the maternal I2 splice and the paternal p.V281L and p.I172N mutations. Sequencing of TG revealed compound heterozygous paternal p.R296* and maternal p.T1416Rfs*30 mutations.
At the age of 9.6 years, he was started on GnRHa, having developed CPP (testicular volumes 6 mL at the age of 9.3 years; basal/ peak LH and FSH 0.5/12.6 and 2.5/9.9 IU/L, respectively). At 13.8 years of age, his growth rate was 0.82 cm/year, with a bone age of 15.5 years; therefore, GnRHa was discontinued. At the age of 15.4 years, he had reached his near-final height of 148.5 cm (SDS -2.77). His weight was 64.2 kg (SDS +0.86), and his BMI 29.11 (SDS +2.51).
Sibling 4 (Fig. 1 , II:6) She was referred at 9.81 years with a history of pubarche at 7 years, accelerated growth velocity (7 cm/year [SDS +1.6]) and an advanced bone age of 11.4 years. No signs of puberty or clitoral hypertrophy were detected at diagnosis. Basal 17-OHP was 49 nmol/L. Synacthen test showed a suboptimal peak cortisol of 385 nmol/L and a peak 17-OHP of 144 nmol/L and thus she was commenced on hydrocortisone (Table 1) . She was compound hetero- 
Discussion
We report the unusual co-occurrence of 2 rare autosomal recessive conditions, CAH due to CYP21A2 mutations and CH due to mutations in TG in a family originating from unrelated parents.
Our cases represent a striking description of genotypephenotype variability of CAH in members of the same family. Mutations resulting in complete inactivation of 21-hydroxylase lead to an SW phenotype, while those that reduce enzyme activity to 2% cause the SV phenotype and those that reduce activity to more than 10% cause the NC phenotype [2] . Of note, the wide range of clinical manifestations of 21-hydroxylase deficiency represents a disease continuum and there is often a fine line between the NC and SV types of CAH, as there is between SW and SV CAH in the absence of an actual SW crisis. The phenotype of CAH should be predicted by the least severe mutation. However, a study including 1,507 families with CAH demonstrated a direct genotype-phenotype correlation in fewer than 50% of affected individuals. The I2 splice mutation activates cryptic splice acceptor sites, resulting in severe enzyme impairment. Although this constitutes the most frequent mutation causing SW CAH, a genotypephenotype discordance may be due to alternate splicing allowing variable enzyme activity [1] .
The p.I172N mutation disrupts a hydrophobic interaction which is crucial in maintaining the enzyme conformation, thus affecting relatively severely the enzyme activity [3] . However, in a recent study, 76% of the individuals who were compound heterozygotes for this mutation and a severe mutation had the SV phenotype while 23% had the SW phenotype, and 1% even had an NC form [1] . The p.V281L mutation causes mild enzyme impairment due to changes in the enzyme tertiary structure [4] . Patients carrying a severe CYP21A2 mutation and the p.V281L mutation usually present with the NC form of CAH, but there is evidence suggesting that these patients have higher 17-OHP concentrations which might predict a more severe phenotype as compared to those who are homozygous for the p.V281L mutation, regardless of gender and age [5] . In our family, siblings 1 and 3 presented with a severe SW form, when an SV or even a NC form would have been predicted. Moreover, although the specific combinations of mutations in the father and in sibling 2 should result in an NC form, they were asymptomatic, indicating a so-called cryptic form of NC CAH [6] . On the other hand, sibling 4, despite genotypic similarity to sibling 2, presented with signs of hyperandrogenism. Several hypotheses have been suggested to explain genotype-phenotype discordance. Subtle variations in transcriptional regulation or downstream protein translation may account for reduced enzyme activity. Hence, the marginal enzymatic function of the p.I172N mutant may not always be sufficient to prevent SW. In studies relying, as in our case, on the detection of a panel of common mutations, additional mutations might be missed [1] . Finally, genetic or environmental factors and individual androgen sensitivity may influence phenotype [7] . Therefore, it has been suggested that selected cases with genotype-phenotype discordance may benefit from whole-exome sequencing [1] .
CAH was poorly controlled in our patients, mainly due to poor compliance. Despite a prompt suppression of early-onset puberty, siblings 1 and 3 reached a final height <2 SD below the mid-parental height, mainly attributable to advanced bone maturation. Although CPP is a wellknown complication of CAH, the age of menarche in inadequately treated girls is late [8] , and a small proportion of women do not undergo menarche [9] . Such patients with CAH are often obese and have insulin insensitivity and polycystic ovaries. All siblings from our kindred (except for sibling 2) presented with overweight/obesity, which probably has a multifactorial pathogenesis. In the light of poor compliance with glucocorticoid replacement therapy, steroid treatment may not have a major role; on the other hand, it can be hypothesized that inadequately treated hypothyroidism may have contributed to weight gain in siblings 1 and 3. However, other factors such as CAH itself, CAH-related adrenomedullary hypofunction, familial or environmental factors might have played a role in the pathogenesis of obesity [10] . Of note, in our patients, obesity had an early onset, thus contributing to the advanced bone age, precocious sexual maturation, insulin insensitivity, and hyperandrogenism.
In addition to these complications, sibling 1 presented with a right adrenal mass, with radiological features consistent with an adenoma. The prevalence of adrenal adenomas in patients with CAH varies in different case series from 82% of cases [11, 12] to 0% [13] , with reports of adrenal adenoma also in NC CAH [5] . The aetiology of such complications is unclear, but the correlation found between adrenal nodules and adrenal volume points toward a role of excess ACTH stimulation [14] ics in the pathogenesis of adrenal tumours is uncertain. Results of the CaHASE study in 153 adults with CAH showed no association between health outcomes of CAH and genotype [15] . On the other hand, studies on subjects with adrenal tumours showed an increased incidence of CYP21A2 mutations and an exaggerated 17-OHP response after ACTH stimulation in up to 70% of cases, thus suggesting a pathogenic role of impaired 21-hydroxylase activity [16, 17] . Finally, other factors, such as a direct effect of sex steroids, LH, and angiotensin II, might be involved [18] .
Our cases are complicated by the coexistence of poorly controlled CH in the 2 siblings with the most severe form of CAH. One of the TG mutations (p.R296*) is known to be pathogenic [19] , while the maternally inherited c.4246_4255delACGTTCCCAG (p.T1416Rfs*30) mutation is novel. The first mutation consists of a C-to-T transition at position 886 in exon 7, resulting in a premature stop codon [19] . Such a mutation truncates TG before the carboxy-terminal acetylcholinesterase homology (ACHE-like) domain, affecting conformational maturation and cellular export of TG [20] . Although functional studies for the p.T1416Rfs*30 mutation are not available, the mutant TG is predicted to lack the ACHE-like domain, thus supporting a pathogenic consequence.
Although TG mutations are usually associated with a goitre, which may develop from the antenatal period to an adult age [21, 22] , this was absent in our hypothyroid siblings. The biochemical spectrum of TG mutations is broad, ranging from severe cases to moderate hypothyroidism and even normal thyroid function. Of note, sibling 1 displayed severe hypothyroidism at diagnosis, while sibling 3 had normal FT4 concentrations at diagnosis, but experienced hypothyroxinaemia during followup. When adequately treated, patients with moderate hypothyroidism do not have physical impairment and/or mental retardation; therefore, learning difficulties in our hypothyroid patients are probably a consequence of noncompliance with thyroxine therapy since the first few months of life. Intrafamilial variability of CH due to TG mutations has been previously reported [19] , and it is probably attributable to variability of phenotypic expression of the defective TG protein [23] .
To conclude, our cases highlight the importance of optimal disease control and exemplify the genotype-phenotype discordance of CAH and CH in members of the same family. This must be borne in mind when predicting phenotype in prenatal testing and when evaluating relatives of CAH patients. In selected cases, whole-exome or genome sequencing may shed further light. Finally, establishing the molecular basis of CH may guide follow-up, and confirm recurrence risk.
